1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. REPLIGEN CORP.

Repligen Corp. XNAS: RGEN

Repligen Corp. Live Share Price Today, Share Analysis and Chart

Momentum Trap
Download real time

136.48 -2.86 (-2.05%)

31.84% Fall from 52W High

108.3K XNAS Volume

XNAS 21 Mar, 2025 11:50 AM (EDT)

Watchlist

Portfolio

Share

Repligen Corp. Key Metrics

Select

Market Capitalization

High in industry
7,663.2

PE TTM

Negative PE TTM
-300.4

PEG TTM

High in industry
1.7

Price to Book

High in industry
18.8

Institutional holding current Qtr %

High in industry
102.1

Revenue Growth Qtr YoY %

Below industry Median
0.6

Operating Revenue growth TTM %

Below industry Median
0.3

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-105.9

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-171.7

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-5

Piotroski Score

Below industry Median
3

Rel Perf vs Sector quarter%

-14.2
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
22.2 / 100
Valuation Score
Expensive Valuation
8.5 / 100
Momentum Score
Technically Neutral
44.2 / 100
Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
191
1Yr Price target upside is 40%
15 analysts

2

S

15

W

0

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Repligen Corp. Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '26600700800900Actual RevenueAvg. Estimate
Hit

Repligen Corp.'s Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

Current EPS
-0.5
Avg. Estimate
1
Low Estimate
0.9
High Estimate
1
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 310.9% in FY25

Consensus Recommendation

19 ANALYST Recommendations
BUY

Created with Highcharts 7.2.26Hold4Buy9Strong Buy

The consensus recommendation from 19 analysts for Repligen Corp. is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Repligen Corp. Stock Analysis

Repligen Corp. stock analysis with key metrics, changes, and trends.

Repligen Corp. MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$634.44 M0.33%positive

Annual Revenue rose 0.33%, in the last year to $634.44 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit$25.51 M171.68%negative

Annual Net Profit fell 171.68% in the last year to $25.51 M. Its sector's average net profit growth for the last fiscal year was -32.35%.

Price to Earning Ratio-300.35-negative

Price to Earning Ratio is -300.35, which is negative.

Stock Price$136.48-30.62%negative

Stock Price fell 30.62% and underperformed its sector by 39.72% in the past year.

Quarterly Revenue$167.55 M0.56%positive

Quarterly Revenue rose 0.56% YoY to $167.55 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$33.87 M105.89%negative

Quarterly Net profit fell 105.89% YoY to $33.87 M. Its sector's average net profit growth YoY for the quarter was -47.35%.

Mutual Fund Holding90.61 %-0.22%negative

Mutual Fund Holding decreased by 0.22% in the last quarter to 90.61.

Promoter Share Holding0.83 %0.02%positive

Promoter Share Holding increased by 0.02% in the most recent quarter to 0.83%.

Institutional Holding102.07 %0%neutral

Institutional Holding remained the same in the last quarter at 102.07%.

VIEW LESS


Loading data..

Repligen Corp. - Company Profile

What does Repligen Corp. do?

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Corp. Management structure

All Gross Remunerations are in USD
Mr. Tony J. Hunt
Director and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Olivier Loeillot
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Jason K. Garland
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year

Repligen Corp. Board of directors

All Gross Remunerations are in USD
Ms. Karen A. Dawes, M.A.
Lead Independent Director
-
2024
Gross Remuneration
Year
Mr. Tony J. Hunt
Executive Chairman of the Board
-
2024
Gross Remuneration
Year
Ms. Margaret A. Pax
Independent Director
-
2024
Gross Remuneration
Year
Mr. Glenn P. Muir
Independent Director
-
2024
Gross Remuneration
Year
Mr. Nicolas M. Barthelemy
Independent Director
-
2024
Gross Remuneration
Year
Dr. Martin D. Madaus,PhD
Independent Director
-
2024
Gross Remuneration
Year

Repligen Corp. FAQ

How is Repligen Corp. today?
Repligen Corp. today is trading in the red, and is down by -2.05% at 136.48.
Repligen Corp. is currently trading down -2.05% on an intraday basis. In the past week the stock fell -4.18%. stock has been down -5.52% in the past quarter and fell -30.62% in the past year. You can view this in the overview section.